Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 9/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 8/20 | 0.44 |
| ▸ | DAGLA | Q9Y4D2 | 3/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.40 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.40 |
| ▸ | THRA | P10827 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30611100 | 1.00 | KEAP1 (0.44) | KEAP1NFE2L2DAGLALMNAMAPT | |
| SCHEMBL30611096 | 0.92 | ALDH1A1 (0.47) | KEAP1NFE2L2LMNAMAPTHTT | |
| SCHEMBL30611099 | 0.92 | ALDH1A1 (0.42) | KEAP1NFE2L2LMNAMAPTHTT | |
| SCHEMBL23663114 | 0.92 | ALDH1A1 (0.42) | KEAP1NFE2L2LMNAMAPTHTT | |
| SCHEMBL23663073 | 0.92 | ALDH1A1 (0.47) | KEAP1NFE2L2LMNAMAPTHTT | |
| SCHEMBL23663233 | 0.88 | LMNA (0.44) | LMNAMAPTHTTNPSR1ALDH1A1 | |
| SCHEMBL29965198 | 0.88 | LMNA (0.44) | LMNAMAPTHTTNPSR1ALDH1A1 | |
| SCHEMBL26401524 | 0.88 | DAGLA (0.46) | KEAP1NFE2L2DAGLALMNAMAPT | |
| SCHEMBL23671394 | 0.86 | BMP1 (0.50) | KEAP1NFE2L2THRATHRB | |
| SCHEMBL23663220 | 0.80 | THRB (0.40) | LMNAMAPTALDH1A1THRATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240190846-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | ECCOGENE INC. | 2024-06-13 | — | — | US | disclosed |
| US-11780825-B2 | Thyroid hormone receptor agonists and use thereof | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2023-10-10 | — | — | US | disclosed |
| US-11780825-B2 | Thyroid hormone receptor agonists and use thereof | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2023-10-10 | — | — | US | disclosed |
| US-20210230146-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | ECCOGENE INC. | 2021-07-29 | — | — | US | disclosed |
| WO-2021143706-A1 | SUBSTITUTED TRIAZINONES AS THYROID HORMONE RECEPTOR AGONISTS | ECCOGENE (SHANGHAI) CO., LTD. (CN) | 2021-07-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230146-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | TSHR, THRA, THRB | KEAP1 3434/4885NFE2L2 3843/4885DAGLA 3679/4885 |
| US-11780825-B2 | Thyroid hormone receptor agonists and use thereof | TSHR, THRA, THRB | KEAP1 3434/4885NFE2L2 3843/4885DAGLA 3679/4885 |
| US-20240190846-A1 | THYROID HORMONE RECEPTOR AGONISTS AND USE THEREOF | TSHR, THRA, THRB | KEAP1 3434/4885NFE2L2 3843/4885DAGLA 3679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.